Company Profile
History
History  (As of July/11/2011)
March, 2005 SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, Tokyo
July, 2005 Head office relocates to Shimbashi, Minato-ku, Tokyo
December, 2005 License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in Japan
March, 2006 Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan Government
March, 2007 License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and Singapore
August, 2008 License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Japan
March, 2009 SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK)
May, 2009 License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and Singapore
September, 2010 SymBio Pharmaceuticals and Eisai launch SYMBENDA® (bendamustine) in Singapore for the treatment of Low-grade Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
October, 2010 SymBio Pharmaceuticals announces NDA Approval of TREAKISYM® (bendamustine) in Japan
December, 2010 SymBio Pharmaceuticals launches TREAKISYM® in Japan
July, 2011 Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101 (rigosertib, a Phase Ⅲ stage multi-kinase inhibitor for Myelodysplastic Syndromes)
October, 2011 SymBio Pharmaceuticals and Eisai launch SYMBENDA® (bendamustine) in Korea for the treatment of Chronic Lymphocytic Leukemia and Multiple Myeloma
October, 2011 Listed on Osaka Securities Exchange JASDAQ Growth Market
February, 2012 SymBio Pharmaceuticals and Innopharmax launch INNOMUSTINE® (bendamustine) in Taiwan for the treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
November, 2014 Head Office relocates to Toranomon, Minato-ku, Tokyo
October, 2015 The Medicines Company(NASDAQ:MDCO) and SymBio Pharmaceuticals completed License Agreement for 「SyB P-1501」 (A combination product for patient-controlled analgesia) development & commercialization rights in Japan
May, 2016 SymBio Pharma USA, Inc. established at Menlo Park, California, USA
August, 2016 SymBio Pharmaceuticals announces the NDA approval of TREAKISYM® (bendamustine) for the additional indication of chronic lymphocytic leukemia in Japan
September, 2016 SymBio Pharmaceuticals announces NDA Approval of TREAKISYM® (bendamustine) Intravenous Infusion 25 mg in Japan
December, 2016 SymBio Pharmaceuticals announces the NDA approval of TREAKISYM® (bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in Japan
September, 2017 Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan
*RTD: Ready-to-dilute, RI: Rapid Infusion